Literature DB >> 18755890

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.

John A Foekens1, Anieta M Sieuwerts, Marcel Smid, Maxime P Look, Vanja de Weerd, Antonius W M Boersma, Jan G M Klijn, Erik A C Wiemer, John W M Martens.   

Abstract

In this study, we quantified 249 mature micro-RNA (miRNA) transcripts in estrogen receptor-positive (ER(+)) primary breast tumors of patients with lymph node-negative (LNN) disease to identify miRNAs associated with metastatic capability. In addition, the prognostic value of the candidate miRNAs was determined in ER(-)/LNN breast cancer. Unsupervised analysis in a prescreening set of 38 patients identified three subgroups predominantly driven by three miRNA signatures: an ER-driven luminal B-associated miRNA signature, a stromal miRNA signature, and an overexpressed miRNA cluster located on chromosome 19q23, but these intrinsic miRNA signatures were not associated with tumor aggressiveness. Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7, miR-128a, miR-210, and miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n = 147) and one miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer (n = 114) and in the clinically important triple-negative subgroup (n = 69) (all P < 0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, miR-7 and miR-516-3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755890      PMCID: PMC2529088          DOI: 10.1073/pnas.0803304105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  microRNAs exhibit high frequency genomic alterations in human cancer.

Authors:  Lin Zhang; Jia Huang; Nuo Yang; Joel Greshock; Molly S Megraw; Antonis Giannakakis; Shun Liang; Tara L Naylor; Andrea Barchetti; Michelle R Ward; George Yao; Angelica Medina; Ann O'brien-Jenkins; Dionyssios Katsaros; Artemis Hatzigeorgiou; Phyllis A Gimotty; Barbara L Weber; George Coukos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 2.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

3.  Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

Authors:  John A Foekens; David Atkins; Yi Zhang; Fred C G J Sweep; Nadia Harbeck; Angelo Paradiso; Tanja Cufer; Anieta M Sieuwerts; Dmitri Talantov; Paul N Span; Vivianne C G Tjan-Heijnen; Alfredo F Zito; Katja Specht; Heinz Hoefler; Rastko Golouh; Francesco Schittulli; Manfred Schmitt; Louk V A M Beex; Jan G M Klijn; Yixin Wang
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

4.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Authors:  Daniel S Oh; Melissa A Troester; Jerry Usary; Zhiyuan Hu; Xiaping He; Cheng Fan; Junyuan Wu; Lisa A Carey; Charles M Perou
Journal:  J Clin Oncol       Date:  2006-02-27       Impact factor: 44.544

5.  Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.

Authors:  Patrick Urban; Vincent Vuaroqueaux; Martin Labuhn; Mauro Delorenzi; Pratyaksha Wirapati; Edward Wight; Hans-Jörg Senn; Christopher Benz; Urs Eppenberger; Serenella Eppenberger-Castori
Journal:  J Clin Oncol       Date:  2006-09-10       Impact factor: 44.544

6.  How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Authors:  Anieta M Sieuwerts; Marion E Meijer-van Gelder; Mieke Timmermans; Anita M A C Trapman; Roberto Rodriguez Garcia; Miranda Arnold; Anneke J W Goedheer; Henk Portengen; Jan G M Klijn; John A Foekens
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

7.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

8.  Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Authors:  Anieta M Sieuwerts; Maxime P Look; Marion E Meijer-van Gelder; Mieke Timmermans; Anita M A C Trapman; Roberto Rodriguez Garcia; Miranda Arnold; Anneke J W Goedheer; Vanja de Weerd; Henk Portengen; Jan G M Klijn; John A Foekens
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

9.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

Authors:  Christos Sotiriou; Pratyaksha Wirapati; Sherene Loi; Adrian Harris; Steve Fox; Johanna Smeds; Hans Nordgren; Pierre Farmer; Viviane Praz; Benjamin Haibe-Kains; Christine Desmedt; Denis Larsimont; Fatima Cardoso; Hans Peterse; Dimitry Nuyten; Marc Buyse; Marc J Van de Vijver; Jonas Bergh; Martine Piccart; Mauro Delorenzi
Journal:  J Natl Cancer Inst       Date:  2006-02-15       Impact factor: 13.506

10.  Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.

Authors:  Jen-Tsan Chi; Zhen Wang; Dimitry S A Nuyten; Edwin H Rodriguez; Marci E Schaner; Ali Salim; Yun Wang; Gunnar B Kristensen; Aslaug Helland; Anne-Lise Børresen-Dale; Amato Giaccia; Michael T Longaker; Trevor Hastie; George P Yang; Marc J van de Vijver; Patrick O Brown
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

View more
  162 in total

1.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.

Authors:  Eun-Jung Jung; Libero Santarpia; Juyeon Kim; Francisco J Esteva; Erica Moretti; Aman U Buzdar; Angelo Di Leo; Xiao-Feng Le; Robert C Bast; Soon-Tae Park; Lajos Pusztai; George A Calin
Journal:  Cancer       Date:  2011-10-05       Impact factor: 6.860

2.  Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women.

Authors:  Anieta M Sieuwerts; Giuseppina De Napoli; Anne van Galen; Helenius J Kloosterboer; Vanja de Weerd; Hong Zhang; John W M Martens; John A Foekens; Christian De Geyter
Journal:  Mol Oncol       Date:  2011-09-16       Impact factor: 6.603

3.  Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples.

Authors:  Mio Kitano; Reza Rahbari; Erin E Patterson; Seth M Steinberg; Nijaguna B Prasad; Yongchun Wang; Martha A Zeiger; Electron Kebebew
Journal:  Thyroid       Date:  2012-02-03       Impact factor: 6.568

Review 4.  Expression patterns of placental microRNAs.

Authors:  Jean-Francois Mouillet; Tianjiao Chu; Yoel Sadovsky
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-03-21

5.  The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.

Authors:  Isabelle Bar; Ahmad Merhi; Fadi Abdel-Sater; Abduelhakem Ben Addi; Sara Sollennita; Jean-Luc Canon; Paul Delrée
Journal:  J Histochem Cytochem       Date:  2017-04-12       Impact factor: 2.479

6.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.

Authors:  Stefano Volinia; Marco Galasso; Maria Elena Sana; Timothy F Wise; Jeff Palatini; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 7.  Transcriptional regulation of mammalian miRNA genes.

Authors:  Brian C Schanen; Xiaoman Li
Journal:  Genomics       Date:  2010-10-23       Impact factor: 5.736

8.  miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4.

Authors:  Hiroshi Okuda; Fei Xing; Puspa R Pandey; Sambad Sharma; Misako Watabe; Sudha K Pai; Yin-Yuan Mo; Megumi Iiizumi-Gairani; Shigeru Hirota; Yin Liu; Kerui Wu; Radhika Pochampally; Kounosuke Watabe
Journal:  Cancer Res       Date:  2013-02-05       Impact factor: 12.701

9.  Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.

Authors:  Meihua Li; Kyle F Lee; Yuntao Lu; Ian Clarke; David Shih; Charles Eberhart; V Peter Collins; Tim Van Meter; Daniel Picard; Limei Zhou; Paul C Boutros; Piergiorgio Modena; Muh-Lii Liang; Steve W Scherer; Eric Bouffet; James T Rutka; Scott L Pomeroy; Ching C Lau; Michael D Taylor; Amar Gajjar; Peter B Dirks; Cynthia E Hawkins; Annie Huang
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

10.  The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.

Authors:  Selma Masri; Zheng Liu; Sheryl Phung; Emily Wang; Yate-Ching Yuan; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2010-01-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.